化学学报 ›› 2020, Vol. 78 ›› Issue (7): 642-656.DOI: 10.6023/A20040116 上一篇    下一篇

综述

活性氧响应型抗肿瘤前药研究进展

张留伟, 陈麒先, 王静云   

  1. 大连理工大学生物工程学院 大连 116024
  • 投稿日期:2020-04-24 发布日期:2020-06-11
  • 通讯作者: 陈麒先, 王静云 E-mail:qixian@dlut.edu.cn;wangjingyun67@dlut.edu.cn
  • 作者简介:张留伟,男,大连理工大学生物化工系在读博士生,目前研究方向为生物纳米材料和抗肿瘤前药的设计、制备及其在肿瘤治疗方面的应用.
    陈麒先,男,大连理工大学生物工程学院特聘研究员,师从美国工程院院士、日本东京大学Prof.Kazunori Kataoka (片冈一则教授),曾担任美国麻省理工学院(MIT)化学系(Prof.Jeremiah A.Johnson研究室)博士后研究员,致力于化学、生物、医学交叉学科研究工作,目前研究方向包括纳米医学、高分子自组装、基因治疗等,尤其强调基因/药物递送技术在顽固性癌症以及中枢神经疾病治疗上的应用价值.
    王静云,女,教授,博士生导师.2001年毕业于大连理工大学获得博士学位,2002~2004年美国西北大学(Northwestern University)化学系博士后,主要从事活细胞内生物分子可视化荧光探针和生物纳米新材料的研究.
  • 基金资助:
    项目受国家自然科学基金面上项目(No.21878041)和兴辽英才计划基金项目(XLYC1807184)资助.

Advances in Reactive Oxygen Species Responsive Anti-cancer Prodrugs

Zhang Liuwei, Chen Qixian, Wang Jingyun   

  1. School of Bioengineering, Dalian University of Technology, Dalian 116024
  • Received:2020-04-24 Published:2020-06-11
  • Supported by:
    Project supported by the National Natural Science Foundation of China (No. 21878041) and Talent Project of Revitalizing Liaoning (XLYC1807184).

活性氧(ROS)在机体信号转导和代谢中起着至关重要的作用,而ROS水平的升高与多种病变(癌症和炎症等)息息相关,基于肿瘤组织高水平ROS开发的肿瘤特异杀伤性前药策略,在增强药效和药物选择性方面提供了一种新颖的方法.本综述介绍了目前用于构建抗肿瘤前药的ROS敏感键:芳基硼酸/酯、烷基硫/硒醚、硫缩酮、过氧草酸酯、氨基丙烯酸酯、噻唑烷酮和α-酮酰胺等,并且详叙了基于这些敏感键设计的前药在抗肿瘤方向上的应用,同时探讨了现有ROS响应型前药系统的研究进展和局限性,并对未来的研究方向进行了展望.

关键词: 活性氧, ROS响应, 前药, 药物递送, 肿瘤治疗

Reactive oxygen species (ROS) are categorized as a class of instantaneous intermediate products of oxygen, which are usually produced by a single electron continuous reduction of O2. Examples include hydrogen peroxide (H2O2), superoxide anion (O2-), hydroxyl radical (HO·), hypochlorite radical (OCl-) and singlet oxygen (1O2). The endogenous ROS arise from three major resources:mitochondrial electron transport chain (Mito-ETC), endoplasmic reticulum (ER) and NADPH oxidase (NOX). The produced ROS play vital roles in physiological functions including modulation of functions of proteins, regulation of cell signaling, mediation of inflammation, and elimination of pathogens. However, the cumulative ROS level in vivo could elicit oxidative stress, which is implicated in a multitude of diseases including cancer, autoimmune diseases, inflammation, cardiovascular diseases, neurodegenerative diseases. This abnormal biochemical alteration in tumors has inspired researchers to exploit the relatively high levels of ROS for development of ROS-responsive prodrug systems. In recent years, ROS-responsive prodrug systems based on a spectrum of ROS-sensitive linkers have been designed and developed with aim of precision tumor therapy. Herein, in this review, we would like to illustrate ROS-sensitive linkers developed to date including arylboronic acid or ester, alkyl thioether or selenide, thioketal, peroxalate ester, aminoacrylate, thiazolidinone and α-ketoamide, and elucidate the underlying molecular oxidation mechanism. Furthermore, the design of ROS-responsive prodrugs based on these sensitive linkers and their applications in anti-cancer therapy were reviewed. Additionally, the existing problems and the future research perspectives of prodrug systems were also discussed.

Key words: reactive oxygen species, ROS-responsive, prodrug, drug delivery, anti-cancer therapy